• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.

作者信息

Athyros Vasilios Gabriel, Doumas Michael, Karagiannis Asterios

机构信息

Aristotelian University, Greece.

Aristotelian University, Greece.

出版信息

Indian Heart J. 2016 Sep-Oct;68(5):596-598. doi: 10.1016/j.ihj.2016.02.022. Epub 2016 Mar 10.

DOI:10.1016/j.ihj.2016.02.022
PMID:27773395
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5079131/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4232/5079131/22177e78ab19/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4232/5079131/22177e78ab19/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4232/5079131/22177e78ab19/gr1.jpg

相似文献

1
Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action.亚洲印度人与西方白人在他汀类药物治疗后残余血脂异常/心血管风险的差异。呼吁采取行动。
Indian Heart J. 2016 Sep-Oct;68(5):596-598. doi: 10.1016/j.ihj.2016.02.022. Epub 2016 Mar 10.
2
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.“不打破就不修复”：对 ACCORD 血脂研究正反结果的评论。
Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.
3
Evolving Role of Non-Statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future.非他汀类疗法在血脂异常管理和降低心血管风险中的作用演变：过去、现在与未来
Pharmacotherapy. 2018 Feb;38(2):164-171. doi: 10.1002/phar.2074. Epub 2018 Jan 10.
4
Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.代谢综合征血脂异常的管理：超越他汀类药物治疗。
Metab Syndr Relat Disord. 2012 Jun;10(3):159-60. doi: 10.1089/met.2012.1500. Epub 2012 May 8.
5
Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?残余风险与高密度脂蛋白胆固醇水平：二者是否存在关联？
Rev Cardiovasc Med. 2011;12(2):e55-9.
6
[Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].[心血管并发症的残余风险及其通过联合降脂药物降低的情况]
Vnitr Lek. 2011 Mar;57(3):313-6.
7
Is lipid management effective for all stages of CKD?血脂管理对 CKD 的所有阶段都有效吗？
Blood Purif. 2013;35(1-3):26-30. doi: 10.1159/000345932. Epub 2013 Jan 22.
8
Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.法国他汀类药物治疗后的残余血脂异常：流行情况和风险分布。
Arch Cardiovasc Dis. 2010 May;103(5):302-9. doi: 10.1016/j.acvd.2010.04.003. Epub 2010 Jun 4.
9
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?平衡的全 PPAR 激动剂贝扎贝特联合他汀类药物：全面的血脂控制和糖尿病预防？
Cardiovasc Diabetol. 2012 Nov 14;11:140. doi: 10.1186/1475-2840-11-140.
10
Safety and efficacy of statins in Asians.他汀类药物在亚洲人群中的安全性与有效性。
Am J Cardiol. 2007 Feb 1;99(3):410-4. doi: 10.1016/j.amjcard.2006.08.051. Epub 2006 Dec 15.

引用本文的文献

1
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.恩格列净对 2 型糖尿病合并心血管疾病患者 EMPA-REG OUTCOME 临床试验中亚洲和非亚洲人群心血管和住院事件总负担的影响。
Diabetes Obes Metab. 2022 Apr;24(4):662-674. doi: 10.1111/dom.14626. Epub 2022 Feb 9.

本文引用的文献

1
Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study.印度首次发生急性冠状动脉事件的成年人中的他汀类药物治疗/降脂治疗：尽管接受他汀类药物治疗仍存在血脂异常残留和混合异常（REMAINS）研究。
Indian Heart J. 2016 Sep-Oct;68(5):646-654. doi: 10.1016/j.ihj.2015.12.016. Epub 2016 Feb 28.
2
Are western guidelines good enough for Indians? My name is Borat.西方的指导方针对印度人来说足够好吗？我叫博拉特。
Indian Heart J. 2015 Mar-Apr;67(2):85-9. doi: 10.1016/j.ihj.2015.04.001. Epub 2015 May 14.
3
Cholesterol lipoproteins and prevalence of dyslipidemias in urban Asian Indians: a cross sectional study.
城市亚洲印度人中胆固醇脂蛋白与血脂异常患病率：一项横断面研究。
Indian Heart J. 2014 May-Jun;66(3):280-8. doi: 10.1016/j.ihj.2014.03.005. Epub 2014 Apr 16.
4
Residual macrovascular risk in 2013: what have we learned?2013年的残余大血管风险：我们学到了什么？
Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26.
5
Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.联合贝特类药物/他汀类药物治疗与他汀类药物单药治疗的患者心血管事件：急性冠脉综合征以色列调查数据。
PLoS One. 2012;7(4):e35298. doi: 10.1371/journal.pone.0035298. Epub 2012 Apr 16.
6
Combination lipid therapy in type 2 diabetes.2型糖尿病的联合降脂治疗。
N Engl J Med. 2010 Aug 12;363(7):692-4; author reply 694-5. doi: 10.1056/NEJMc1006407.
7
Effects of combination lipid therapy in type 2 diabetes mellitus.2 型糖尿病的联合降脂治疗效果。
N Engl J Med. 2010 Apr 29;362(17):1563-74. doi: 10.1056/NEJMoa1001282. Epub 2010 Mar 14.
8
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.残余风险降低倡议：呼吁采取行动降低血脂异常患者的残余血管风险。
Am J Cardiol. 2008 Nov 17;102(10 Suppl):1K-34K. doi: 10.1016/S0002-9149(08)01833-X.
9
Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis.为什么南亚人如此容易患中心性肥胖及其致动脉粥样硬化后果？脂肪组织溢出假说。
Int J Epidemiol. 2007 Feb;36(1):220-5. doi: 10.1093/ije/dyl245.
10
Statin-fibrate combinations in patients with combined hyperlipedemia.他汀类药物与贝特类药物联合用于混合性高脂血症患者。
Atherosclerosis. 2001 Mar;155(1):263-4. doi: 10.1016/s0021-9150(00)00726-7.